前列腺癌放射电阻的蛋白质基因组学
Roni Haas1,2,3,4, Gavin Frame5,6, Shahbaz Khan7
1Department of Human Genetics, University of California, Los Angeles, Los Angeles, California.
Cancer research communications
|August 21, 2024
概括
前列腺癌的放射电阻涉及基因组不稳定性和DNA修复缺陷. 鉴定出DNA聚合酶甲基 (POLQ) 是抗辐射的关键调节剂,为改善放射治疗结果提供了潜在的标.
科学领域:
- 在瘤学瘤学.
- 辐射瘤学 辐射瘤学
- 分子生物学分子生物学
背景情况:
- 放射治疗是前列腺癌的主要治疗方法.
- 有侵略性的抗辐射复发发生,但它们的分子基础尚不清楚.
- 现代放射治疗趋向于低分离,需要对放射电阻机制有更深入的了解.
研究的目的:
- 描述前列腺癌放射电阻的分子基础.
- 调查传统与低分离辐射疗法的差异效应.
- 为了确定克服放射电阻的新目标.
主要方法:
- 来自前列腺癌细胞的基因组,转录和蛋白质组数据的分析.
- 用常规分离和低分离放射治疗治疗细胞.
- 在模型系统和患者队列中验证临床前候选者.
主要成果:
- 放射治疗耐药性与大规模的基因组不稳定性和受损的DNA不匹配修复有关.
- 前列腺癌驱动基因显示改变了RNA和蛋白质表达和辐射后亚细胞局部化.
- 与低分化相比,传统的分化诱导了更具侵略性的生物分子反应.
- 在患者数据中,DNA聚合酶甲基 (POLQ) 被确定为放射性敏感剂,其活性与放射电阻相关.
结论:
- 前列腺癌的放射电阻是复杂的,涉及基因组不稳定性和DNA修复调制.
- 生物分子对放射治疗的反应取决于分离计划.
- POLQ是放射电阻的关键调节器,也是提高放射治疗疗效的潜在治疗标.
更多相关视频
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
6.8K
06:44Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
13.3K
相关概念视频
Cancer-Critical Genes I: Proto-oncogenes
8.7K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.7K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
